small nucleolar RNA, H/ACA box 71BGenealiases: RNU71B · U71b
Q-omics provides the consensus-scored SNORA71B profile across patient tissues and cancer cell-line models. SNORA71B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA71B is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNORA71B RNA expression shows 19,225 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where SNORA71B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA71B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA71B survival associations across molecular data types. SNORA71B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA71B RNA expression–survival associations across cancer types. High SNORA71B expression shows unfavorable associations in KIRC, UCEC and LGG, but favorable associations in READ, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA71B RNA expression.
This table summarizes SNORA71B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA71B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA71B shows higher tumor expression in COAD, HNSC, READ, STAD, LUSC and KIRC. The COAD box plot shows higher SNORA71B RNA expression in tumor versus normal tissue (log2 FC = +1.748, t-test p < 0.001).
This table shows molecular features associated with SNORA71B in patient tissues and cancer cell lines. In patient samples, SNORA71B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
